Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ101 vs daily recombinant human growth hormone in pediatric growth hormone deficiency
CTR20202305Phase 3Completed
- Sponsor
- I-Mab
- Start
- Dec 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of eftansomatropin alfa in growth hormone deficiency (GHD), sponsored by I-Mab. Started Dec 2020; status: completed.
02
Drugs
eftansomatropin alfa
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on CTR20202305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202305.